Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N8-GP surgical efficacy and safety study in haemophilia A
NL-OMON44118Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Haemostatic effect during surgery. Started May 2013; status: active, not recruiting.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON44118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44118.